Ellagic acid metabolism as a source of dietary MR1 ligands
The Journal of Immunology · 2026
DOI: 10.1093/jimmun/vkaf346 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von David O'Sullivan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Malaghan Institute of Medical Research, Wellington, New Zealand. Hauptthemen laut MEDLINE: Ellagic Acid, Mucosal-Associated Invariant T Cells, Histocompatibility Antigens Class I, Minor Histocompatibility Antigens. Die Arbeit nennt 68 Literaturangaben. Gefördert von: New Zealand Ministry of Business, Innovation and Employment High-Value Nutrition National Science Challenge, New Zealand Health Research Council Independent Research Organization Fund, National Health and Medical Research Council Investigator.
Abstract (Originalsprache)
MR1 is an major histocompatibility complex class I–like molecule that presents small molecule metabolites to MR1-restricted T cells that include a major population of highly conserved T cells known as mucosal-associated invariant T (MAIT) cells. MAIT cells recognize bacterial riboflavin pathway–derived neoantigens and are being attributed an increasing number of immune and homeostatic functions. However, the chemical breadth and diversity of MR1-restricted ligands remain to be fully elucidated. Due to the largely (poly)cyclic structure of known MR1 ligands, we aimed to identify MR1 ligands from a library of dietary phenolic metabolites. Competitive MAIT cell inhibition assays using both cell lines and primary cells isolated from human blood identified gut microbial metabolites of ellagitannins that include ellagic acid (EA), urolithin D (UroD), and UroM5 as potential MR1 ligands. Fluorescence polarization binding assays demonstrated that EA, UroM5, UroC, and UroB bound to MR1, and we provide a structural basis for EA presentation by MR1. Overall, our findings indicate that EA metabolism provides dietary MR1 ligands that inhibit T cell receptor–dependent MAIT cell activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Malaghan Institute of Medical Research, Wellington, New Zealand.
- High-Value Nutrition National Science Challenge, Auckland, New Zealand.
- Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
- Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom.
ORCID-Profile: Anthony W Purcell
Förderung
- New Zealand Ministry of Business, Innovation and Employment High-Value Nutrition National Science Challenge
- New Zealand Health Research Council Independent Research Organization Fund
- National Health and Medical Research Council Investigator
Zitieren
APA
O'Sullivan, D., Wang, C. J. H., Tang, J. S., Stephens, R., Faulkner, S., Gell, K., Li, Y., Cait, A., McInerney, M., Purcell, A. W., Rossjohn, J., Le Nours, J., & Gasser, O. (2026). Ellagic acid metabolism as a source of dietary MR1 ligands. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf346
Vancouver
O'Sullivan D, Wang CJH, Tang JS, Stephens R, Faulkner S, Gell K, et al. Ellagic acid metabolism as a source of dietary MR1 ligands. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkaf346
BibTeX
@article{OSullivan2026,
author = {O'Sullivan, David and Wang, Carl J H and Tang, Jeffry S and Stephens, Ruth and Faulkner, Sophie and Gell, Katie and Li, Yanyan and Cait, Alissa and McInerney, Mitchell and Purcell, Anthony W and Rossjohn, Jamie and Le Nours, Jérôme and Gasser, Olivier},
title = {Ellagic acid metabolism as a source of dietary MR1 ligands},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkaf346}
}
EUVIMED